FINWIRES · TerminalLIVE
FINWIRES

$VRTX

19 stories mentioning VRTXUpdated just now

Every FINWIRES story that references VRTX, newest first.

Wire

Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says

Vertex Pharmaceuticals (VRTX) remains well positioned heading into the second half of 2026 as several pipeline catalysts approach, while upcoming competitor cystic fibrosis data is unlikely to materially affect its outlook, UBS Securities said in a note Tuesday.The investment firm said expectations around the competitive threat have already moderated, noting Vertex's once-daily Alyftrek has shown strong efficacy and that the rival study's narrower patient population may limit its read-through to Vertex.UBS said it remains most optimistic about phase III data for inaxaplin in APOL1-mediated kidney disease expected in early 2027, saying positive results could position Vertex as the first company to market in the indication and further expand its nephrology franchise.It also highlighted Phase II data expected this fall in APOL1-mediated kidney disease patients with Type 2 diabetes or moderate proteinuria, a population that could expand the drug's addressable market by 50% to 100%.UBS has a buy rating on the stock with a price target of $585.Price: $480.04, Change: $+9.32, Percent Change: +1.98%

$VRTX
Wire

Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says

Vertex Pharmaceuticals (VRTX) reported a solid Q2 and raised its outlook, highlighting the strength of its core business and pipeline, RBC Capital Markets said in a note emailed Tuesday.The analysts said the stock could benefit once the Sionna Therapeutics (SION) data overhang clears, with upcoming catalysts including the launch of new products, the expected closing of the Crinetics Pharmaceuticals (CRNX) deal, and additional pipeline readouts.The stock does not fully reflect the potential upside from pipeline opportunities, including kidney programs, expansion of povetacicept into autoimmune diseases such as IgA nephropathy and generalized myasthenia gravis, and the longer-term potential of suzetrigine in chronic pain, the analysts added."We believe that given Vertex's strong core revenue, a pipeline that is increasingly becoming more mature, and with optionality to further diversify pipeline with external [business development,] shares should command a higher valuation," the analysts said.RBC lowered its price target on Vertex Pharmaceuticals to $570 from $577 and kept its outperform rating on the stock.Price: $477.03, Change: $+6.30, Percent Change: +1.34%

$CRNX$SION$VRTX
Research

Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19

Vertex Pharmaceuticals (VRTX) has an average rating of overweight and mean price target of $558.17, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$VRTX
Wire

UBS Adjusts Vertex Pharmaceuticals Price Target to $585 From $545, Maintains Buy Rating

Vertex Pharmaceuticals (VRTX) has an average rating of overweight and mean price target of $555, according to analysts polled by FactSet.Price: $483.16, Change: $-2.23, Percent Change: -0.46%

$VRTX
Wire

RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $577 From $570

Vertex Pharmaceuticals (VRTX) has an average rating of overweight and mean price target of $5Price: $485.78, Change: $-12.65, Percent Change: -2.54%

$VRTX
Wire

Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says

Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday.As of July 6, the NYSE Arca Pharmaceutical Index has gained 11% and the Nasdaq Biotechnology Index has added 18%, compared with a 10% gain for the S&P 500 Index, with recent stock performance driven more by changes in valuation multiples than by earnings estimate revisions, the investment bank said.Morgan Stanley said its US Equity Strategy team expects the sector to benefit from broader market leadership. Biotech remains one of the most rate-sensitive sectors, and historically, the sector has delivered nearly 20% annualized returns during falling-rate environments, according to the note.In addition, merger and acquisition activity remains healthy, with several $5 billion to $10 billion deals recently announced, including AbbVie (ABBV) purchasing Apogee (APGE), and Vertex Pharmaceuticals (VRTX) buying Crinetics Pharmaceuticals (CRNX), the investment bank said.Morgan Stanley adjusted its price targets on Biogen (BIIB) to $222 from $224, Amgen (AMGN) to $333 from $340, Gilead Sciences (GILD) to $166 from $168, AbbVie to $279 from $278, Moderna (MRNA) to $39 from $33, BioNTech (BNTX) to $119 from $126, Regeneron Pharmaceuticals (REGN) to $730 from $788, Johnson & Johnson (JNJ) to $284 from $283, and Eli Lilly (LLY) to $1,347 from $1,344.Shares of Biogen, Amgen, Gilead, AbbVie, Moderna, BioNTech, Regeneron, Johnson & Johnson, and Eli Lilly were down 2%, 0.1%, 0.8%, 0.4%, 7%, 1.9%, 1.9%, 0.4%, and 0.5% respectively, in Wednesday trading.Price: $201.67, Change: $-4.03, Percent Change: -1.96%

$ABBV$AMGN$APGE$BIIB$BNTX$CRNX$GILD$JNJ$LLY$MRNA$REGN$VRTX
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1.4%.In corporate news, Vertex Pharmaceuticals (VRTX) agreed to buy endocrine disease drugmaker Crinetics Pharmaceuticals (CRNX) for a total equity value of about $10 billion. Crinetics shares jumped 98%, and Vertex was down 1.2%.Eli Lilly (LLY) Canada said Tuesday that Health Canada has approved Mounjaro for pediatric patients aged 10 to 17 with type 2 diabetes. Lilly shares rose 2.7%.Vera Therapeutics' (VERA) Trutakna has been approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy, the US Food and Drug Administration said in a Tuesday statement. Vera Therapeutics shares jumped by more than 7%.AstraZeneca (AZN) has signed an agreement to access Helix's genomic datasets to support research for drug discovery and development, Helix said Tuesday. AstraZeneca shares added 1.4%.

$AZN$CRNX$LLY$VERA$VRTX
Insider Trading

Vertex Pharmaceuticals Insider Sold Shares Worth $1,827,900, According to a Recent SEC Filing

Carmen Bozic, Chief Medical Officer and Executive Vice President, on June 15, 2026, sold 4,062 shares in Vertex Pharmaceuticals (VRTX) for $1,827,900. Following the Form 4 filing with the SEC, Bozic has control over a total of 16,953 common shares of the company, with 16,953 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/875320/000087532026000235/xslF345X05/wk-form4_1781727153.xml

$VRTX
Insider Trading

Vertex Pharmaceuticals Insider Sold Shares Worth $785,250, According to a Recent SEC Filing

Carmen Bozic, Chief Medical Officer and Executive Vice President, on June 05, 2026, sold 1,745 shares in Vertex Pharmaceuticals (VRTX) for $785,250. Following the Form 4 filing with the SEC, Bozic has control over a total of 21,015 common shares of the company, with 21,015 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/875320/000087532026000233/xslF345X05/wk-form4_1781036661.xml

$VRTX
Insider Trading

Vertex Pharmaceuticals Insider Sold Shares Worth $888,300, According to a Recent SEC Filing

Carmen Bozic, Executive Vice President and Chief Medical Officer, on May 29, 2026, sold 1,974 shares in Vertex Pharmaceuticals (VRTX) for $888,300. Following the Form 4 filing with the SEC, Bozic has control over a total of 22,760 common shares of the company, with 22,760 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/875320/000087532026000228/xslF345X05/wk-form4_1780430661.xml

$VRTX
Wire

Vertex Says Health Canada Accepts Suzetrigine Application for Review

Vertex Pharmaceuticals (VRTX) said Thursday that Health Canada accepted for review its new drug submission for suzetrigine for the treatment of moderate-to-severe acute pain in adults.Suzetrigine is an investigational, oral, selective NaV1.8 pain signal inhibitor and represents a new class of oral pain medicine that is neither an opioid nor a nonsteroidal anti-inflammatory drug, the company said.The company added that it intends for the regulatory review of suzetrigine to be part of an aligned review with Canadian Health Technology Assessment Organizations, including Canada's Drug Agency and Quebec's Institut national d'excellence en sante et en services sociaux.Suzetrigine was approved by the US Food and Drug Administration under the brand name Journavx in January 2025 and received breakthrough therapy, fast track and priority review designations, the biotechnology company said.Price: $432.66, Change: $+2.22, Percent Change: +0.52%

$VRTX
Insider Trading

Vertex Pharmaceuticals Insider Sold Shares Worth $613,971, According to a Recent SEC Filing

Carmen Bozic, Chief Medical Officer and Executive Vice President, on May 15, 2026, sold 1,354 shares in Vertex Pharmaceuticals (VRTX) for $613,971. Following the Form 4 filing with the SEC, Bozic has control over a total of 24,734 common shares of the company, with 24,734 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/875320/000087532026000225/xslF345X05/wk-form4_1779221059.xml

$VRTX
Insider Trading

Vertex Pharmaceuticals Insider Sold Shares Worth $469,222, According to a Recent SEC Filing

Joy Liu, Executive Vice President and Chief Legal Officer, on May 01, 2026, sold 1,104 shares in Vertex Pharmaceuticals (VRTX) for $469,222. Following the Form 4 filing with the SEC, Liu has control over a total of 20,729 common shares of the company, with 20,729 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/875320/000087532026000183/xslF345X05/wk-form4_1778015480.xml

$VRTX
Wire

Vertex Pharmaceuticals Confident in Emerging Renal Franchise, Oppenheimer Says

Vertex Pharmaceuticals' (VRTX) management remains confident in its emerging renal franchise, suggesting it could rival or even exceed its cystic fibrosis franchise eventually, Oppenheimer said in a Tuesday note.The strong uptake of Alyftrek is encouraging, and Oppenheimer expects continued growth in US and international markets, driven by adoption among treatment-naive patients, those who previously discontinued cystic fibrosis therapy, and patients who switched to Alyftrek, according to the note.Uptake of Alyftrek among younger patients and more access in Europe should support long-term growth, according to the note. For Journavx, management remains confident in tripling total scripts in 2026, the brokerage said.Management remains confident in Pove's profile, and the recent submission completion for Pove suggests a potential FDA decision by year-end, according to the note.Oppenheimer said Inaxaplin represents the next key catalyst, with the phase 2 AMPLIFIED study readout now expected in H2, compared with the prior mid-2026 guidance.Oppenheimer maintained an outperform rating on Vertex Pharmaceuticals with a price target of $600.Price: $423.92, Change: $-5.93, Percent Change: -1.38%

$VRTX
Asia Markets

US Equity Futures Gain Pre-Bell as Traders Keep Eye on Potential Re-Escalation of Middle East Hostilities

US equity futures were higher pre-bell Tuesday as traders kept a close watch on the potential re-escalation of hostilities in the Middle East.Dow Jones Industrial Average futures were 0.4% higher, S&P 500 futures were up 0.5%, and Nasdaq futures were 0.8% higher.The UAE said that it was attacked by Iranian drones and missiles, while the US said it sank Iranian boats in the Strait of Hormuz.President Donald Trump had said that the US would help guide vessels stranded in the Persian Gulf. In a post Monday on Truth Social, he said that a South Korean cargo ship had been damaged by Iran, but the US had shot down seven Iranian small boats."Other than the South Korean Ship, there has been, at this moment, no damage going through the Strait," Trump said.Traders digested the latest round of earnings, with Palantir Technologies (PLTR) and Vertex Pharmaceuticals (VRTX) reporting higher Q1 adjusted earnings and revenue. HSBC (HSBC) also posted an increase in Q1 earnings and revenue.Oil prices were lower, with front-month global benchmark North Sea Brent crude down 2.2% at $111.91 per barrel and US West Texas Intermediate crude 3.2% lower at $103.04 per barrel.The US international trade deficit widened to $60.31 billion in March from a $57.78 billion gap in February, compared with a $61.0 billion gap expected in a survey compiled by Bloomberg as of 7:40 am ET.The S&P Global purchasing managers' index composite final report for April, due at 9:45 am ET, is seen reporting 52.1 versus 52.0 previously.March new home sales report, due at 10 am ET, is expected to post a 652,000 annual rate. The April Institute for Supply Management's services index is projected at 53.7 versus 54.0 previously. March job openings from the US Department of Labor's Job Openings and Labor Turnover Survey are expected to come in at 6.850 million compared with 6.882 million in the prior month.Federal Reserve Vice Chair for Supervision Michelle Bowman and Fed Governor Michael Barr are due to speak today.In other world markets, Japan's Nikkei and China's Shanghai Composite were closed due to public holidays. Hong Kong's Hang Seng ended 0.8% lower. The UK's FTSE 100 was down 1.4%, and Germany's DAX index was 1.6% higher in Europe's early afternoon session.In equities, Intel (INTC) shares were up 3.8% after Bloomberg reported the Apple (AAPL) has held early discussions with the company and Samsung Electronics on producing key device processors in the US. Anheuser-Busch InBev (BUD) stock was up 6.6% after the company reported fiscal Q1 underlying earnings and revenue that beat analysts' estimates. Pinterest (PINS) shares were up 18% after the company posted higher Q1 non-GAAP earnings and revenue that beat analysts' consensus.On the losing side, Palantir and HSBC shares were down 1.3% and 3.9%, respectively, after they reported Q1 financial results. Shopify (SHOP) stock was 5.9% lower after the company reported a Q1 loss while analysts expected earnings.

Dow JonesNasdaq CompositeS&P 500$AAPL$BUD$HSBC$INTC$PINS$PLTR$SHOP$VRTX
Japan

US Equity Futures Higher Pre-Bell as Traders Keep Eye on Potential Re-Escalation of Middle East Hostilities

US equity futures were higher pre-bell Tuesday as traders kept a close watch on the potential re-escalation of hostilities in the Middle East.Dow Jones Industrial Average futures were 0.3% higher, S&P 500 futures were up 0.4%, and Nasdaq futures were 0.6% higher.The UAE said that it was attacked by Iranian drones and missiles, while the US said it sank Iranian boats in the Strait of Hormuz.President Donald Trump had said that the US would help guide vessels stranded in the Persian Gulf. In a post Monday on Truth Social, he said that a South Korean cargo ship had been damaged by Iran, but the US had shot down seven Iranian small boats."Other than the South Korean Ship, there has been, at this moment, no damage going through the Strait," Trump said.Traders digested the latest round of earnings, with Palantir Technologies (PLTR) and Vertex Pharmaceuticals (VRTX) reporting higher Q1 adjusted earnings and revenue. HSBC (HSBC) also posted a Q1 increase in earnings and revenue.Oil prices were lower, with front-month global benchmark North Sea Brent crude down 1.6% at $112.67 per barrel and US West Texas Intermediate crude 2.4% lower at $103.94 per barrel.The international trade in goods report, scheduled for release at 8:30 am ET, is expected to post a deficit widening to $61 billion from $57.3 billion in the prior month, according to estimates compiled by Bloomberg. The purchasing managers' index composite final report for April, due at 9:45 am ET, i is seen coming in at 52.1 versus 52.0 previously.March new home sales, due at 10 am ET, is seen coming in at a 652,000 annual rate. The April Institute for Supply Management's services index is projected at 53.7 versus 54.0 previously. March job openings from the Department of Labor's Job Openings and Labor Turnover Survey are expected to come in at 6.850 million compared with 6.882 million in the prior month.Federal Reserve Vice Chair for Supervision Michelle Bowman is slated to speak at 10 am, while Fed Governor Michael Barr speaks at 12:30 pm.

Dow JonesNasdaq CompositeS&P 500$HSBC$PLTR$VRTX
Research

Research Alert: CFRA Retains Buy Rating On Shares Of Vertex Pharmaceuticals Incorporated

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 results, we lower our target price to $535 from $579, 24.4x our 2027 EPS, a discount to VRTX's 10-year historical forward P/E average. We maintain our 2026 EPS view of $19.40 and our 2027 EPS estimate at $21.92. VRTX's Q1 2026 was marked by robust revenue growth, successful commercial execution of new products, and significant progress in its clinical pipeline, particularly in the renal space. The company's CF franchise remains the primary revenue driver, while new products like Casgevy and Gernavics are beginning to contribute meaningfully to growth, accounting for approximately 25% of the total product revenue growth in Q1. Pipeline advancement remains robust, in our view, with the completion of the rolling BLA submission for povetacicept in IgA nephropathy representing a significant regulatory milestone. Using a Priority Review Voucher, VRTX expects an expedited six-month FDA review timeline, which is encouraging.

$VRTX
Research

Research Alert: Vertex Reports Mixed Q1, Reaffirms Full-year 2026 Financial Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Vertex delivered mixed Q1 results with revenue of $2.99B (+8% Y/Y) falling $10M short of expectations, though non-GAAP EPS of $4.47 (+10% Y/Y) beat the consensus by $0.16. The quarter demonstrated successful execution of VRTX's multi-product launch strategy, with ALYFTREK generating $424.4M (vs. $53.9M prior year), CASGEVY contributing $42.9M (+202% Y/Y), and JOURNAVX adding $29.0M in its second commercialization year. Recent FDA label extensions for ALYFTREK and TRIKAFTA expanded CF patient eligibility to ~95% in the U.S., adding roughly 800 more patients. VRTX maintained its 2026 guidance unchanged with total revenue expectations of $12.95B-$13.1B and non-CF product revenue of $500M or greater. We view the operating leverage positively, with revenue growth outpacing expense increases, and believe the diversification strategy beyond CF continues to gain traction with meaningful contributions from newly launched therapies across multiple therapeutic areas.

$VRTX
Wire

GUIDANCE: (VRTX) Vertex Pharmaceuticals Expects 2026 Revenue Range $12.95B-$13.1B, vs. FactSet Est of $13.05B

GUIDANCE: (VRTX) Vertex Pharmaceuticals Expects 2026 Revenue Range $12.95B-$13.1B, vs. FactSet Est of $13.05B

$VRTX

Track with the FINWIRES app suite

FolioX
FolioX
Track VRTX in your portfolio
WheelAI
WheelAI
Analyze VRTX options with the wheel strategy
StockInsider
StockInsider
See market sentiment on VRTX